Abstract 3435
Background
Adult primary malignant brain tumours are rare; however, they have a devastating impact and a poor prognosis (Ford et al., 2012). For the past seven years the National Cancer Patient Experience Survey (Quality Health, 2014) has reported the care of brain tumour patients as being less positive compared to other cancer sites, possibly due to unmet care needs. The Aims of this research were: - To explore registered medical nurses’ experiences of the care needs of adult patients with a primary brain tumour. - To identify possible gaps in knowledge and skills that limit the provision of optimal care.
Methods
The project adopted a qualitative methodological approach using semi-structured interviews to collect and analyse data to reflect the experiences of medical nurses’ in the aforementioned care context. Three participants volunteered, who met the inclusion/exclusion criteria. Participants were registered nurses who had worked on the oncology/haematology Triage Unit for 12 months or more so that they had meaningful reflection.
Results
Themes emerged from the collection and analysis of data. Three main themes emphasised that the experience was: challenging; involved holistic care and depended on nurses’ knowledge and experience. Published literature identified that brain tumour patients were different to other cancer patients because they require more nursing time to address their complex care needs. The findings highlighted that senior nurses were significantly more knowledgeable, holistic and aware of patient needs.
Conclusions
Junior nurses felt they had very limited experience, confidence or knowledge to care for adult patients with a primary brain tumour. They acknowledged that education and training was essential to allow staff involved in the care of adult patients with a primary brain tumour to feel confident enough to be able to assess and care for the complex needs of this group of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Birmingham City University.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
4543 - Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
Presenter: Stéphane Dalle
Session: Poster Display session 3
Resources:
Abstract
4523 - Prognostic Factors for efficacy of Ipilimumab used after AntiPD1 and/or BRAF+MEK inhibitors in Melanoma Patients: an Italian Melanoma Intergroup study
Presenter: Riccardo Marconcini
Session: Poster Display session 3
Resources:
Abstract
3632 - Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy
Presenter: Adriana Hepner
Session: Poster Display session 3
Resources:
Abstract
3732 - Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy.
Presenter: Kazi Nahar
Session: Poster Display session 3
Resources:
Abstract
5005 - Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
Presenter: Michiel van Zeijl
Session: Poster Display session 3
Resources:
Abstract
5524 - Utilization of Real-World Data to Assess the Effectiveness of Immune Checkpoint Inhibitors (ICIs) in Elderly Patients with Metastatic Melanoma
Presenter: D Scott Ernst
Session: Poster Display session 3
Resources:
Abstract
5884 - Tumor mutational burden and response to PD-1 inhibitors: an analysis of 89 cases of metastatic melanoma.
Presenter: Léa Dousset
Session: Poster Display session 3
Resources:
Abstract
3120 - Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.
Presenter: Elisa Rozeman
Session: Poster Display session 3
Resources:
Abstract
2157 - Immune status defined by molecular information layers predicts response to pembrolizumab treatment in advanced melanoma
Presenter: Guillermo Prado-Vázquez
Session: Poster Display session 3
Resources:
Abstract
2553 - Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy
Presenter: Shahneen Sandhu
Session: Poster Display session 3
Resources:
Abstract